Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells

K. Tominaga, T. Shimamura, N. Kimura, T. Murayama, D. Matsubara, H. Kanauchi, A. Niida, S. Shimizu, K. Nishioka, E. I. Tsuji, M. Yano, S. Sugano, Y. Shimono, H. Ishii, H. Saya, M. Mori, K. Akashi, K. I. Tada, T. Ogawa, A. TojoS. Miyano, N. Gotoh

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The transcription factor nuclear factor-κB (NF-κB) has important roles for tumorigenesis, but how it regulates cancer stem cells (CSCs) remains largely unclear. We identified insulin-like growth factor 2 (IGF2) is a key target of NF-κB activated by HER2/HER3 signaling to form tumor spheres in breast cancer cells. The IGF2 receptor, IGF1 R, was expressed at high levels in CSC-enriched populations in primary breast cancer cells. Moreover, IGF2-PI3K (IGF2-phosphatidyl inositol 3 kinase) signaling induced expression of a stemness transcription factor, inhibitor of DNA-binding 1 (ID1), and IGF2 itself. ID1 knockdown greatly reduced IGF2 expression, and tumor sphere formation. Finally, treatment with anti-IGF1/2 antibodies blocked tumorigenesis derived from the IGF1R high CSC-enriched population in a patient-derived xenograft model. Thus, NF-κB may trigger IGF2-ID1-IGF2-positive feedback circuits that allow cancer stem-like cells to appear. Then, they may become addicted to the circuits. As the circuits are the Achilles' heels of CSCs, it will be critical to break them for eradication of CSCs.

Original languageEnglish
Pages (from-to)1276-1286
Number of pages11
JournalOncogene
Volume36
Issue number9
DOIs
Publication statusPublished - Mar 2 2017

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Tominaga, K., Shimamura, T., Kimura, N., Murayama, T., Matsubara, D., Kanauchi, H., ... Gotoh, N. (2017). Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells. Oncogene, 36(9), 1276-1286. https://doi.org/10.1038/onc.2016.293